Transdermal testosterone therapy has received regulatory approval for the treatment of hypoactive sexual desire dysfunction (HSDD) in postmenopausal women. It is an effective treatment option for persistent low sexual desire that continues after exclusion or targeted management of reversible biopsychosocial factors.
Testosterone therapy has been shown to improve low sexual desire associated with distress in postmenopausal women. Until recently, the only options for testosterone therapy in women in Australia were a formulation for women approved only in Western Australia, testosterone formulations for men with dose modification, or compounded therapies. In November 2020, the TGA approved a transdermal testosterone 1% formulation for the treatment of hypoactive sexual desire dysfunction (HSDD) in postmenopausal women.1 This article reviews the physiology of testosterone in women and the indications and prescribing details for transdermal testosterone therapy in women.